CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Novelos Therapeutics, Inc.  (NVLT)
Other Ticker:  
 

Novelos Therapeutics's Quick Ratio

NVLT's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Novelos Therapeutics's Cash & cash equivalent, this led to improvement in Novelos Therapeutics's Quick Ratio to 1.12, Quick Ratio remained below Novelos Therapeutics, Inc. average.

Within Major Pharmaceutical Preparations industry 159 other companies have achieved higher Quick Ratio than Novelos Therapeutics in third quarter 2013. While Quick Ratio total ranking has improved so far during the III Quarter 2013 to 1333, from total ranking in the second quarter 2013 at 1541.

Explain Quick Ratio?
How much Cash & cash equivalents NVLT´s has?
What are NVLT´s Current Liabilities?


NVLT Quick Ratio (Sep 30 2013)
III. Quarter		 (Jun 30 2013)
II. Quarter		 (Mar 31 2013)
I. Quarter		 (Dec 31 2012)
IV. Quarter		 (Sep 30 2012)
Y / Y Current Liabilities Change 528.28 % 858.12 % 1202.13 % 45.49 % -
Y / Y Cash & cash equivalent Change -8.62 % -18.3 % 106.05 % -14.9 % -
Quick Ratio MRQ 1.12 0.97 1.2 6.46 7.67
NVLT's Total Ranking # 1333 # 1541 # 1541 # 1517 # 262
Seq. Current Liabilities Change -24 % -7.61 % 799.78 % -0.56 % 15.9 %
Seq. Cash & cash equivalent Change -12.2 % -25.69 % 67.3 % -16.28 % -21.5 %

New: More NVLT's historic Quick Ratios >>


Quick Ratio third quarter 2013 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 160
Healthcare Sector # 305
Overall Market # 1333


Quick Ratio Statistics
High Average Low
11.33 5.92 0.97
(Jun 30 2012)   (Jun 30 2013)




Financial Statements
Novelos Therapeutics's Current Liabilities $ 5 Millions Visit NVLT's Balance sheet
Novelos Therapeutics's Cash & cash equivalent $ 5 Millions Visit NVLT's Balance sheet
Source of NVLT's Sales Visit NVLT's Sales by Geography


Cumulative Novelos Therapeutics's Quick Ratio

NVLT's Quick Ratio for the trailling 12 Months

NVLT Quick Ratio

 (Sep 30 2013)
III. Quarter		 (Jun 30 2013)
II. Quarter		 (Mar 31 2013)
I. Quarter		 (Dec 31 2012)
IV. Quarter		 (Sep 30 2012)
Y / Y Current Liabilities TTM Growth 528.28 % 858.12 % 1202.13 % 45.49 % -
Y / Y Cash & cash equivalent TTM Growth -8.62 % -18.3 % 106.05 % -14.9 % -
Quick Ratio TTM 1.31 1.71 2.93 8.21 9.34
Total Ranking TTM # 355 # 209 # 96 # 39 # 28
Seq. Current Liabilities TTM Growth -24 % -7.61 % 799.78 % -0.56 % 15.9 %
Seq. Cash & cash equivalent TTM Growth -12.2 % -25.69 % 67.3 % -16.28 % -21.5 %

Quick ratio ranking by company, industry and sector >> Back to NVLT Financial Strength Comparisons >> Go to Compare NVLT Quick Ratio to its Competitors

On the trailing twelve months basis Due to decline in Current Liabilities in the III Quarter 2013 to $4.63 millions, cumulative Quick Ratio decreased to 1.31 below the Novelos Therapeutics, Inc. average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 38 other companies have achieved higher Quick Ratio than Novelos Therapeutics. While Quick Ratio overall ranking has improved so far to 319, from total ranking during the twelve months ending second quarter 2013 at 1465.

Explain Quick Ratio?
How much Cash & cash equivalents NVLT´s has?
What are NVLT´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 39
Healthcare Sector # 128
Within the Market # 1333


trailing twelve months Quick Ratio Statistics
High Average Low
9.34 4.7 1.31
(Sep 30 2012)   (Sep 30 2013)




Companies with similar Quick Ratio in the quarter ending Sep 30 2013, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2013 MRQ Cash & cash equivalentSep 30 2013 MRQ Current Liabilities
Celgene Corp  3.01 $ 5,847.300  Millions$ 1,941.300  Millions
Lftd Partners Inc   3.01 $ 0.509  Millions$ 0.169  Millions
Merrimack Pharmaceuticals Inc  3.00 $ 182.586  Millions$ 60.859  Millions
Medicines Co  2.71 $ 462.360  Millions$ 170.346  Millions
Bolt Biotherapeutics Inc   2.70 $ 25.170  Millions$ 9.319  Millions
Allergan plc  2.68 $ 3,210.900  Millions$ 1,199.700  Millions
Veru Inc   2.62 $ 8.922  Millions$ 3.407  Millions
Odonate Therapeutics Inc   2.59 $ 0.910  Millions$ 0.351  Millions
Opko Health Inc   2.53 $ 180.838  Millions$ 71.377  Millions
Seelos Therapeutics inc   2.49 $ 20.951  Millions$ 8.400  Millions
Avid Bioservices Inc   2.37 $ 44.443  Millions$ 18.767  Millions
Assertio Holdings inc   2.36 $ 80.576  Millions$ 34.119  Millions
Nektar Therapeutics  2.27 $ 183.550  Millions$ 80.913  Millions
Biomarin Pharmaceutical Inc  2.26 $ 379.651  Millions$ 167.633  Millions
Ibio inc   2.08 $ 3.444  Millions$ 1.653  Millions
Madrigal Pharmaceuticals Inc   2.06 $ 53.384  Millions$ 25.931  Millions
Dara Biosciences, Inc.  2.05 $ 2.585  Millions$ 1.261  Millions
Chembio Diagnostics Inc   2.04 $ 8.046  Millions$ 3.935  Millions
Lannett Company Inc  1.88 $ 45.799  Millions$ 24.299  Millions
Oragenics Inc   1.86 $ 8.268  Millions$ 4.453  Millions
Insys Therapeutics, Inc.  1.85 $ 31.346  Millions$ 16.905  Millions
Cytokinetics Incorporated  1.81 $ 81.642  Millions$ 45.011  Millions
Ani Pharmaceuticals Inc  1.78 $ 10.930  Millions$ 6.139  Millions
Alaunos Therapeutics Inc   1.77 $ 23.631  Millions$ 13.362  Millions
Rockwell Medical inc   1.73 $ 31.218  Millions$ 18.072  Millions
Tenax Therapeutics Inc   1.72 $ 2.543  Millions$ 1.477  Millions
Akorn Inc  1.69 $ 75.598  Millions$ 44.640  Millions
Caladrius Biosciences Inc   1.69 $ 16.946  Millions$ 10.036  Millions
Regeneron Pharmaceuticals Inc   1.66 $ 445.323  Millions$ 268.727  Millions
Pfizer Inc  1.65 $ 33,679.000  Millions$ 20,373.000  Millions

Date modified: -0001-11-30T00:00:00+00:00



Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com